Janus-like effects of type I interferon in autoimmune diseases

被引：42

作者：

Axtell, Robert C. ^{[1
]}

Raman, Chander ^{[2
]}

机构：

[1] Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr, Stanford, CA 94305 USA

[2] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA

来源：

IMMUNOLOGICAL REVIEWS | 2012年 / 248卷

基金：

美国国家卫生研究院;

关键词：

interferon; Th17; Th1; autoimmunity; IL-7; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CELL-ACTIVATING FACTOR; NECROSIS-FACTOR-ALPHA; REMITTING MULTIPLE-SCLEROSIS; T-HELPER TYPE-1; NEUROMYELITIS-OPTICA; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; PHASE-I; NEUTRALIZING ANTIBODIES;

D O I：

10.1111/j.1600-065X.2012.01131.x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In multiple sclerosis, type I interferon (IFN) is considered immune-modulatory, and recombinant forms of IFN-beta are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, because type I IFN contributes to the pathologies. Even within the relapsing-remitting multiple sclerosis (RRMS) population, 30-50% of MS patients are non-responsive to this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS. In this article, we discuss the recent advances in the field of autoimmunity and introduce the theory explain how type I IFNs can be pro-inflammatory in disease that is predominantly driven by a Th17 response and are therapeutic when disease is predominantly Th1.

引用

页码：23 / 35

页数：13

共 152 条

[1] SUPPRESSION OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS BY INTERFERON [J].

ABREU, SL .

IMMUNOLOGICAL COMMUNICATIONS, 1982, 11 (01) :1-7

[2] Heterogeneity of human effector CD4+ T cells [J].

Annunziato, Francesco ;

Romagnani, Sergio .

ARTHRITIS RESEARCH & THERAPY, 2009, 11 (06)

[3]

ARIIZUMI K, 1995, J IMMUNOL, V154, P6031

[4]

Arnason BGW, 1999, ANNU REV MED, V50, P291

[5] T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis [J].

Axtell, Robert C. ;

de Jong, Brigit A. ;

Boniface, Katia ;

van der Voort, Laura F. ;

Bhat, Roopa ;

De Sarno, Patrizia ;

Naves, Rodrigo ;

Han, May ;

Zhong, Franklin ;

Castellanos, Jim G. ;

Mair, Robert ;

Christakos, Athena ;

Kolkowitz, Ilan ;

Katz, Liat ;

Killestein, Joep ;

Polman, Chris H. ;

Malefyt, Rene de Waal ;

Steinman, Lawrence ;

Raman, Chander .

NATURE MEDICINE, 2010, 16 (04) :406-U21

[6] Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis [J].

Barkhof, F ;

Filippi, M ;

Miller, DH ;

Scheltens, P ;

Campi, A ;

Polman, CH ;

Comi, G ;

Ader, HJ ;

Losseff, N ;

Valk, J .

BRAIN, 1997, 120 :2059-2069

[7] B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time [J].

Becker-Merok, A. ;

Nikolaisen, C. ;

Nossent, H. C. .

LUPUS, 2006, 15 (09) :570-576

[8] CNS demyelination during anti-tumor necrosis factor alpha therapy [J].

Bellesi, M ;

Logullo, F ;

Di Bella, P ;

Provinciali, L .

JOURNAL OF NEUROLOGY, 2006, 253 (05) :668-669

[9] Interferon and granulopoiesis signatures in systemic lupus erythematosus blood [J].

Bennett, L ;

Palucka, AK ;

Arce, E ;

Cantrell, V ;

Borvak, J ;

Banchereau, J ;

Pascual, V .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (06) :711-723

[10]

Benveniste Etty N, 2007, Sci STKE, V2007, ppe70, DOI 10.1126/stke.4162007pe70

← 1 2 3 4 5 6 7 8 9 10 →